IJTLD Open (ISSN: 3005-7590) is open access and fully compliant with Plan S.
IJTLD Open includes a broader range of article types than the traditional IJTLD, including: Editorials, Meeting reports, Original Articles (including methodology papers, qualitative research and operational research), State of the Art Reviews, Guidelines/Consensus documents, Systematic Reviews and Meta-Analysis, Perspectives, Minireviews, Letters, Case reports, Case series and Correspondence.
We publish high impact research for the continuing education of academics, clinicians and all other health personnel working on respiratory diseases and lung health, with the aim of improving policy and practise.
IJTLD OPEN is open access and free to read. Also, authors retain copyright and can freely distribute the PDF or upload it to any website. As a consequence, open access articles are highly downloaded and more highly cited.
Click the links below to read our content on PubMed Central, Ingenta.com or via links from the Directory of Open Access Journals (DOAJ), or PubMed. .
While preparing their article, authors should refer to the Instructions for Authors to check that they have complied with our requirements – see links below.
Once complete, authors should submit their manuscripts at http://mc.manuscriptcentral.com/ijtld
We invite authors with OA funding to submit their papers (including Editorials, Original Articles, Letters and Case Series) to IJTLD OPEN.
We welcome submissions on the development of vaccines, diagnostics and medicines for the prevention, management and control of TB and all other respiratory diseases.
This includes basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
For all queries please e-mail the Editorial Office
Sponsorship
Supplements and article series are a highly-effective way of highlighting a specific topic to researchers, clinicians and decision makers in respiratory health.
Being an Open Access journal, IJTLD OPEN has no barriers to access and can reach readers in health centres, medical, university and pharmaceutical institutes, along with civil society, patients and carers.
All content will be freely available on Ingenta.com and we will have regular mailings to highlight the latest sponsored content.
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD, IJTLD OPEN and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
TB research amidst the COVID-19 pandemic
To ensure that scientific research of immediate concern is shared as rapidly as possible, The Union is fast-tracking accepted articles…
Mortality of TB-COVID-19 coinfection in India
To ensure that scientific research of immediate concern is shared as rapidly as possible, The Union is fast-tracking accepted articles…
Tobacco use and quitting behaviour during COVID-19 lockdown
A survey has revealed that nearly two thirds of tobacco users reported an intention to quit smoking during lockdown in Chennai, India.
TB and COVID-19 co-infection: rationale and aims of a global study
The potential impact of COVID-19 on TB patients and services continues to generate significant attention. Although several concerns have been raised, scientific evidence remains modest.
Urgent call for continuity of TB services during the COVID-19 pandemic in China
Our survey revealed that COVID-19 led to a significant disruption in TB diagnosis and care at major hospitals throughout China. We urgently call for additional investment directed toward improving the availability of diagnostics and therapeutics such that equitable access to care can be maintained during times of crisis.
Impact of COVID-19 on TB diagnosis in Northeastern Brazil
In the context of the global pandemic, there is an urgent need for research that elucidates the relationship between COVID-19 and TB, the adoption of strategies that protect TB patients from infection by SARS-CoV-2, and the adoption and/or strengthening of strategies to ensure the diagnosis of TB during the pandemic period.